Loss of H3C14 enhances GCB resistance, promotes malignant phenotypes, reduces apoptosis and alters the expression of key GCB‐metabolizing enzymes, highlighting its potential as a therapeutic target in GCB‐refractory bladder cancer. Here, H3C14 is linked to urinary bladder cancer.